HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Test (opens in a new window) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosen, E. L. Articles by Mankoff, D. A. Search for Related Content PubMed PubMed Citation Articles by Rosen, E. L. Articles by Mankoff, D. A. Related Collections Breast (Imaging and Interventional) Nuclear Medicine Oncologic Imaging Computed Tomography

FDG PET, PET/CT, and Breast Cancer Imaging¹

¹ From the Department of Radiology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave East, G3-200, Seattle, WA 98109-1023. Received March 16, 2007; revision requested May 1 and received June 18; accepted June 22. Supported in part by grants CA72064, CA90771, and CA42045 from the National Institutes of Health. E.L.R. is an author for McGraw-Hill, New York, NY; D.A.M. receives research support from General Electric, Fairfield, Conn; the other author has no financial relationships to disclose. Address correspondence to E.L.R. (e-mail: elrosen{at}seattlecca.org).

Currently, the clinical role of positron emission tomography (PET) and PET/computed tomography (CT) in patients with breast cancer is to provide additional information in select scenarios in which results of conventional imaging are indeterminate or of limited utility. There is currently no clinical role for fluorodeoxyglucose (FDG) PET in detection of breast cancer or evaluation of axillary lymph nodes, but these are areas of active research. FDG PET is complementary to conventional staging procedures and should not be a replacement for either bone scintigraphy or diagnostic CT. FDG PET and PET/CT have been shown to be particularly useful in the restaging of breast cancer, in evaluation of response to therapy, and as a problem-solving method when results of conventional imaging are equivocal. In these situations, FDG PET often demonstrates locoregional or unsuspected distant disease that affects management. PET has demonstrated a particular capability for evaluation of chemotherapy response in both patients with locally advanced breast carcinoma and those with metastatic disease.

© RSNA, 2007

This article has been cited by other articles:

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions J. Nucl. Med., May 1, 2009; 50(5): 738 - 748. [Abstract] [Full Text] [PDF]

				J. H. Lee, E. L. Rosen, and D. A. Mankoff The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1--Overview, Detection, and Staging J. Nucl. Med., April 1, 2009; 50(4): 569 - 581. [Abstract] [Full Text] [PDF]

				S. Carkaci, H. A. Macapinlac, M. Cristofanilli, O. Mawlawi, E. Rohren, A. M. Gonzalez Angulo, S. Dawood, E. Resetkova, H. T. Le-Petross, and W.-T. Yang Retrospective Study of 18F-FDG PET/CT in the Diagnosis of Inflammatory Breast Cancer: Preliminary Data J. Nucl. Med., February 1, 2009; 50(2): 231 - 238. [Abstract] [Full Text] [PDF]